Galena Biopharma Acquires Mills Pharmaceuticals, LLC

Go back to Galena Biopharma Acquires Mills Pharmaceuticals, LLC

Roth Capital Raises PT on Galena Biopharma (GALE) Following Mills Pharmaceuticals Purchase

January 13, 2014 9:31 AM EST

Roth Capital maintains its Buy rating on Galena Biopharma (Nasdaq: GALE), but raises its price target from $7 up to $11 following the... More